PDCD1 and neoplasm: Consistent with the findings of the current study, research has indicated that administration of RNase1 in mice leads to a reduction in the secretion of proinflammatory cytokines.[29] Moreover, we previously revealed RNase1 to be involved in conferring resistance to Nivolumab, an anti‐PD‐1 antibody, by promoting the polarization of macrophages toward a tumor‐associated phenotype in HCC.[11e] These observations suggest that RNase1 might play an immunosuppressive role in the TME.